Unique Features of the Mode of Action of ET-743
Open Access
- 1 June 2002
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 7 (3) , 210-216
- https://doi.org/10.1634/theoncologist.7-3-210
Abstract
This paper describes the current knowledge of the primary mode of action of a natural product, ecteinascidin 743 (ET-743), derived from the marine tunicate Ecteinascidia turbinata. ET-743 was initially selected for preclinical development because of its potent antitumor activity observed against several human solid tumor types. In vitro, the drug is cytotoxic in the nanomolar range, and in the case of some very sensitive cell lines, in the picomolar range. The large potency differences observed among several solid tumor types indicate that this compound possesses some tumor selectivity, but the molecular basis of these differential effects remains to be elucidated. The present studies were undertaken to evaluate the mechanism of action of ET-743 in this context. The available information on ET-743 binding to DNA and its effects on transcriptional regulation point to a unique behavior of this drug, as it independently affects specific gene transcription in a promoter-dependent way. In addition, ET-743 shows a peculiar pattern of selectivity in cells with different defects in their DNA-repair pathways. These results highlight a unique property of ET-743, possibly explaining why it possesses antitumor activity against tumors that are refractory to standard anticancer drugs, all of which certainly act by mechanisms that are different from that of ET-743.Keywords
This publication has 18 references indexed in Scilit:
- The inefficiency of incisions of ecteinascidin 743–DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agentChemistry & Biology, 2001
- Ecteinascidin-743: A Marine-Derived Compound in Advanced, Pretreated Sarcoma Patients—Preliminary Evidence of ActivityJournal of Clinical Oncology, 2001
- Phase I and Pharmacokinetic Study of Ecteinascidin-743, a New Marine Compound, Administered as a 24-hour Continuous Infusion in Patients With Solid TumorsJournal of Clinical Oncology, 2001
- Ecteinascidin 743: A Minor Groove Alkylator That Bends DNA toward the Major GrooveJournal of Medicinal Chemistry, 1999
- Molecular Basis for the DNA Sequence Selectivity of Ecteinascidin 736 and 743: Evidence for the Dominant Role of Direct Readout via Hydrogen BondingJournal of the American Chemical Society, 1998
- In vitro antitumor activity of the novel marine agent, Ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patientsAnnals of Oncology, 1998
- NMR-Based Model of an Ecteinascidin 743−DNA AdductJournal of the American Chemical Society, 1997
- DNA Sequence- and Structure-Selective Alkylation of Guanine N2 in the DNA Minor Groove by Ecteinascidin 743, a Potent Antitumor Compound from the Caribbean Tunicate Ecteinascidia turbinataBiochemistry, 1996
- Progress in the acquisition of new marine-derived anticancer compounds: development of ecteinascidin-743 (ET-743)Drugs of the Future, 1996
- Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinataThe Journal of Organic Chemistry, 1990